Regeneron (NASDAQ:REGN) shares hit a new 52-week high and low during mid-day trading on Friday . The stock traded as low as $312.80 and last traded at $313.83, with a volume of 256639 shares trading hands. The stock had previously closed at $315.83.
Several research analysts have recently issued reports on the stock. Cowen reaffirmed a “hold” rating and issued a $450.00 target price on shares of Regeneron in a research note on Wednesday, February 7th. BMO Capital Markets raised their target price on shares of Regeneron from $398.00 to $444.00 and gave the company a “market perform” rating in a research note on Thursday, February 8th. BTIG Research reaffirmed a “hold” rating on shares of Regeneron in a research note on Tuesday, March 13th. Jefferies Group reaffirmed a “hold” rating and issued a $380.00 target price on shares of Regeneron in a research note on Thursday, February 8th. Finally, Leerink Swann reduced their target price on shares of Regeneron from $568.00 to $502.00 and set an “outperform” rating on the stock in a research note on Friday, February 9th. Four analysts have rated the stock with a sell rating, seventeen have issued a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $448.72.
The company has a current ratio of 3.82, a quick ratio of 3.18 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $34,013.63, a P/E ratio of 23.43, a P/E/G ratio of 1.03 and a beta of 1.46.
Regeneron (NASDAQ:REGN) last announced its earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 EPS for the quarter, topping the consensus estimate of $4.18 by $1.05. The firm had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.50 billion. Regeneron had a net margin of 20.41% and a return on equity of 28.48%. The business’s quarterly revenue was up 28.9% on a year-over-year basis. During the same period last year, the company posted $3.04 EPS. equities research analysts forecast that Regeneron will post 19.2 EPS for the current year.
In other Regeneron news, Director Joseph L. Goldstein sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 14th. The shares were sold at an average price of $340.00, for a total transaction of $680,000.00. Following the sale, the director now directly owns 14,000 shares in the company, valued at approximately $4,760,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Joseph L. Goldstein sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $325.60, for a total transaction of $325,600.00. The disclosure for this sale can be found here. Insiders have sold a total of 5,000 shares of company stock worth $1,705,640 over the last 90 days. Corporate insiders own 10.80% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the business. Steward Partners Investment Advisory LLC raised its holdings in shares of Regeneron by 495.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company’s stock valued at $138,000 after purchasing an additional 307 shares during the last quarter. Pin Oak Investment Advisors Inc. acquired a new stake in shares of Regeneron in the fourth quarter valued at approximately $152,000. Advisory Services Network LLC raised its holdings in shares of Regeneron by 147.0% in the fourth quarter. Advisory Services Network LLC now owns 447 shares of the biopharmaceutical company’s stock valued at $168,000 after purchasing an additional 266 shares during the last quarter. Mackenzie Financial Corp acquired a new stake in shares of Regeneron in the fourth quarter valued at approximately $204,000. Finally, AE Wealth Management LLC acquired a new stake in shares of Regeneron in the fourth quarter valued at approximately $206,000. Hedge funds and other institutional investors own 66.40% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/22/regeneron-regn-hits-new-52-week-high-and-low-at-312-80.html.
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Receive News & Ratings for Regeneron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron and related companies with MarketBeat.com's FREE daily email newsletter.